Title |
Efficacy of c-Met inhibitor for advanced prostate cancer
|
---|---|
Published in |
BMC Cancer, October 2010
|
DOI | 10.1186/1471-2407-10-556 |
Pubmed ID | |
Authors |
William H Tu, Chunfang Zhu, Curtis Clark, James G Christensen, Zijie Sun |
Abstract |
Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuation of androgen receptor (AR) signalling. This suggested that current androgen ablation therapy for prostate cancer activates c-Met expression and may contribute to development of more aggressive, castration resistant prostate cancer (CRPC). Therefore, we directly assessed the efficacy of c-Met inhibition during androgen ablation on the growth and progression of prostate cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 36 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 33% |
Student > Ph. D. Student | 7 | 19% |
Student > Master | 6 | 17% |
Student > Postgraduate | 3 | 8% |
Student > Bachelor | 1 | 3% |
Other | 5 | 14% |
Unknown | 2 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 33% |
Agricultural and Biological Sciences | 9 | 25% |
Biochemistry, Genetics and Molecular Biology | 7 | 19% |
Mathematics | 1 | 3% |
Computer Science | 1 | 3% |
Other | 3 | 8% |
Unknown | 3 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2013.
All research outputs
#4,160,532
of 22,736,112 outputs
Outputs from BMC Cancer
#1,000
of 8,272 outputs
Outputs of similar age
#18,055
of 98,928 outputs
Outputs of similar age from BMC Cancer
#5
of 47 outputs
Altmetric has tracked 22,736,112 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,272 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 98,928 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.